Planned intervention: On Wednesday April 3rd 05:30 UTC Zenodo will be unavailable for up to 2-10 minutes to perform a storage cluster upgrade.
Published August 15, 2020 | Version v1
Proposal Open

Proposal and protocol for the construction of pEF1-ACE2-IGG2-SMAR vector for gene therapy of SARS-CoV-2

Creators

  • 1. The University Of Sydney

Description

The Coronavirus SARS-CoV-2, the etiological agent of COVID-19. Utilizes cellular ACE2 receptors for the entry of cells. This receptor binds to the receptor binding motif(RBM) of the SARS-CoV-2 S protein with affinity of around 100nM—comparable to a very high affinity monoclonal antibody. Fusion proteins consisting of the ectodomain of ACE2 fused to the Fc region of a human Antibody have been proven to neutralize the SARS-CoV-2 virus in vitro[1][2], and displayed extended serum half-life and lack of toxicity in-vivo[1][2][3]. In addition, this fusion protein have been proven to significantly attenuate SARS-CoV-2 infection In-Vivo using a murine model[1]. Such recombinant proteins have been proposed as a form of therapeutic for COVID-19 patients.

Files

pEF_Episomal_Vector_ACE2_IGG2_K326W_E333S_oligos.txt